The μ-opioid receptor-mediated Gi/o protein and β-arrestin2 signaling pathways both contribute to morphine-induced side effects
- PMID: 38278466
- DOI: 10.1016/j.ejphar.2024.176333
The μ-opioid receptor-mediated Gi/o protein and β-arrestin2 signaling pathways both contribute to morphine-induced side effects
Abstract
The μ-opioid receptor-biased agonist theory holds that Gio protein signaling mediates the analgesic effect of opioids and the related side effects via the β-arrestin2 signaling pathway. A series of μ-opioid-biased agonists have been developed in accordance with this theory, and the FDA has approved TRV130 (as a representative of biased agonists) for marketing. However, several reports have raised the issue of opioid side effects associated with the use of agonists. In this study, five permeable peptides were designed to emulate 11 S/T phosphorylation sites at the μ-opioid receptor (MOR) carboxyl-terminal. In vitro experiments were performed to detect the activation level of G proteins from the cAMP inhibition assay and the β-arrestin2 recruitment by the BRET assay. Designed peptides might effectively interfere with the activation of the Gio and β-arrestin2 pathways when combined with morphine. The resulting morphine-induced tolerance, respiratory inhibition, and constipation in mice showed that the β-arrestin2 pathway was responsible for morphine tolerance while the Gio signaling pathway was involved with respiratory depression and constipation and that these side effects were significantly related to phosphorylation sites S363 and T370. This study may provide new directions for the development of safer and more effective opioid analgesics, and the designed peptides may be an effective tool for exploring the mechanism by which μ-opioid receptors function, with the potential of reducing the side effects that are associated with clinical opioid treatment.
Keywords: Constipation; G(io) pathway; Respiratory depression; Tolerance; β-arrestin2; μ-Opioid receptor.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor.Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16346-16355. doi: 10.1073/pnas.1918264117. Epub 2020 Jun 29. Proc Natl Acad Sci U S A. 2020. PMID: 32601232 Free PMC article.
-
TRV130 partial agonism and capacity to induce anti-nociceptive tolerance revealed through reducing available μ-opioid receptor number.Br J Pharmacol. 2021 Apr;178(8):1855-1868. doi: 10.1111/bph.15409. Epub 2021 Mar 2. Br J Pharmacol. 2021. PMID: 33555037
-
Morphine-induced respiratory depression is independent of β-arrestin2 signalling.Br J Pharmacol. 2020 Jul;177(13):2923-2931. doi: 10.1111/bph.15004. Epub 2020 Feb 17. Br J Pharmacol. 2020. PMID: 32052419 Free PMC article.
-
Novel Opioid Receptor Agonists with Reduced Morphine-like Side Effects.Mini Rev Med Chem. 2018;18(19):1603-1610. doi: 10.2174/1389557518666180716124336. Mini Rev Med Chem. 2018. PMID: 30009707 Review.
-
Biased versus Partial Agonism in the Search for Safer Opioid Analgesics.Molecules. 2020 Aug 25;25(17):3870. doi: 10.3390/molecules25173870. Molecules. 2020. PMID: 32854452 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials